Table 3.
Observed/proposed change in management based on comprehensive genomic profiling (*Documented response or on treatment for at least 3 months).
| Diagnosis | Molecular Alterations | Management Change | Observed Benefit | |
|---|---|---|---|---|
| 1. | Lung adenocarcinoma | EML4-ALK fusion (Variant 1) | Crizotinib | Lost to follow-up |
| 2. | Lung adenocarcinoma | EGFR amplification, G719A | Erlotinib continued | Yes |
| 3. | Lung adenocarcinoma | EGFR G719A, Q701L, amplification | Erlotinib continued | Yes |
| 4. | Lung adenocarcinoma | EGFR E746_A750del MET amplification |
Crizotinib-Erlotinib | Lost to follow-up |
| 5. | Poorly differentiated NSCLC, sarcomatoid morphology | NTRK1 TPM3-NTRK1 fusion | Died prior to giving Crizotinib | N/A |
| 6. | Lung adenocarcinoma | EGFR amplification, exon 19 deletion | Afatinib | Yes |
| 7. | Lung adenocarcinoma | EGFR exon 19 deletion, T790M |
Osimertinib | Yes |
| 8. | Lung adenocarcinoma | ALK EML4-ALK fusion (Variant 1) | Alectinib | Yes |
| 9. | Lung adenocarcinoma | BRCA2 S1099* MET amplification |
Declined participation in MATCH study | N/A |
| 10. | Lung adenocarcinoma | EGFR L858R | Died prior to starting EGFR-TKI | N/A |
| 11. | Lung adenocarcinoma | EGFR exon 19 deletion, T790M, L792F, C797S | Osimertinib continued beyond progression | N/A |
| 12. | Medullary thyroid cancer | RET V804M | Cabozantinib Lenvatinib Phase 1 study of MGCD516 |
Yes |
| 13. | Poorly differentiated NSCLC | MET amplification | Died prior to planned phase 1 trial of MGCD516 | N/A |
| 14. | Poorly differentiated NSCLC | MET amplification | Died prior to planned phase 1 trial of MGCD516 | N/A |
| 15. | Lung adenocarcinoma | EGFR exon 19 deletion (L747_S752del) T790M |
Osimertinib | Yes |
| 16. | Lung adenocarcinoma Urothelial bladder cancer |
Numerous | Clarified primary tumor to be urothelial in origin | Yes |
| 17. | Gastric adenocarcinoma | MSI-High | Pembrolizumab | Yes |
| 18. | Lung adenocarcinoma | EGFR exon 19 deletion (E746_A750del), T790M | Osimertinib | Yes |
| 19. | Lung adenocarcinoma | EGFR amplification, L858R, R776C, T790M MET amplification |
Osimertinib + crizotinib | Yes |
| 20. | Lacrimal duct carcinoma | ERBB2 amplification | Trastuzumab | No |
| 21. | Nasopharyngeal adenoid cystic carcinoma | PIK3CA H1047R | Taselisib on MATCH study | Yes |
| 22. | Lung adenocarcinoma | EGFR exon 19 deletion | Erlotinib after clearance of T790M | No |
| 23. | Thymoma | CDKN2A/B loss KDM6A W1194* |
Phase I/IIa trial of ALRN-6924 in patients with wild typeTP53 | Yes |
| 24. | Invasive ductal breast cancer | CCND1 amplification | Abemaciclib | No |
| 25. | Lung adenocarcinoma | RET KIF5B-RET fusion, RET-KIF5B fusion | Phase 1/1b MGCD516 | Not documented, patient withdrew from study |
| 26. | Lung adenocarcinoma | BRAF V600E | Vemurafenib Dabrafenib +Trametinib |
Yes |
| 27. | Lung adenocarcinoma | EGFR exon 19 deletion | Erlotinib after clearance of T790M | No |
| 28. | Lung adenocarcinoma | EGFR amplification, exon 19 deletion (E746_A750del), T790M | Osimertinib | Yes |
| 29. | Rectal adenocarcinoma | ERBB2 amplification, V777L | Ado-trastuzumab emtansine on MATCH study | Yes |
| 30. | Esophageal adenocarcinoma | ERBB2 amplification | Trastuzumab | Patient lost to follow-up/did not complete treatment |
| 31. | Carcinoma of unknown primary, likely upper GI/pancreaticobiliary origin | MET amplification | Planned for crizotinib but not approved by insurance | N/A |
| 32. | Lung adenocarcinoma | EGFR amplification, L858R, T790M | Osimertinib | Yes |
| 33. | Invasive ductal breast cancer | CCND1 amplification | Palbociclib | No |
| 34. | Lung adenocarcinoma | EGFR exon 19 deletion | Afatinib | Yes |
| 35. | Salivary ductal carcinoma | VEGFA amplification | Sorafenib | No |
| 36. | Colon adenocarcinoma | Numerous | Pembrolizumab based on numerous mutations detected and concern for MSI status | No |
| 37. | Esophageal squamous cell carcinoma | EGFR amplification | Panitumumab | No |
| 38. | Lung adenocarcinoma | ALK EML4-ALK fusion (Variant 3a/b) | Alectinib | Yes |
| 39. | Lung adenocarcinoma | EGFR L964L | Erlotinib | Yes |
| 40. | Follicular dendritic cell sarcoma | AKT2 amplification | Everolimus | Yes |
| 41. | Lung adenocarcinoma | MET H1094R | Died prior to starting crizotinib | N/A |
| 42. | Lung adenocarcinoma | MET exon 14 splice site (D1010N) | Crizotinib | No |
(EGFR, Epidermal growth factor receptor; MATCH, Molecular Analysis for Therapy Choice; TKI, Tyrosine Kinase Inhibitor; MSI, Microsatellite Instability). VEGF-A, Vascular endothelial growth factor A; NSCLC, Non-Small-Cell Lung Cancer; ALK, anaplastic lymphoma kinase; EML4, echinoderm microtubule-associated protein-like 4.